Transparency Market Research has published a new report, titled “Uterine fibroid treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2023.” According to the report, over 20 to 40% of the women during the reproductive ages suffer from uterine fibroid and this in turn is driving the growth of the global uterine fibroid treatment market. As many times fibroids do not cause any symptoms, their size, and location are difficult to determine but cause discomfort, heavy bleeding and pain in the women and this in turn will drive the demand for uterine fibroids treatment.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11123
As per the report, genetic and hormonal imbalance are some of the factors behind the formation of uterine fibroid. The presence of uterine fibroids can be detected through symptoms such as heavy menstrual bleeding, excessive uterine bleeding, abdominal pain, anaemia, infertility, and increased urinary frequency. Apart from physical Mobility, the quality of life of women is also spoiled to a large extent due to uterine fibroid and it is also a key reason for hysterectomy. Therefore, there is a growing need and demand for uterine fibroids treatment which are defective. As of now, the treatment therapy is segmented into medical management, surgical management, oral contraceptives, GnRH agonists, and progestins. In various critical cases, hysterectomy, myomectomy, and ablation are also used.
The absence of a satisfactory medical treatment makes the global uterine fibroids treatment market a potential one in terms of scope of improvement and further growth. In North America alone, 20 million people are suffering from uterine fibroids whereas 24 million European women are suffering from uterine fibroid. Thus, there is a vast pool of patient population and with it a large need for effective uterine fibroids treatment.
On the basis of geography, the global uterine fibroids treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and the rest of the world. Of these, North America and Europe are leading Regional markets for uterine fibroids on a cart of the presence of a large pool of patient population suffering from this issue. The presence of a well-established Healthcare infrastructure, favourable reimbursement policies, and growing adoption of latest technology for the treatment of diseases are some of the other factors helping the developed regions to grow within the market. Asia-pacific is also anticipated to be a key market for uterine fibroid treatment, as per TMR.
Some of major players in uterine fibroid treatment market mentioned in the are Boston Scientific Corporation, C.R. Bard, Cooper Surgical, F. Hoffmann-La Roche Ltd, GE Healthcare, Richard Wolf Medical Instruments and Siemens Medical Solutions, Karl Storz Endoscopy, AbbVie Inc., Bayer AG, AstraZeneca, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline Pharmaceuticals Limited, Novartis AG, and Johnson & Johnson.